Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

August 8, 2025

Study Completion Date

August 8, 2025

Conditions

Neoplasm

Interventions

DRUG

[14C] AZD6738

radiolabeled AZD6738 / ceralasertib

DRUG

AZD6738 / ceralasertib

Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR

Trial Locations (2)

Research Site, Liverpool

Research Site, London